| ￥2600 | |
| Z06427-100 | |
|
|
|
|
|
|
|
|
|
| Species | Rat | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its ability to inhibit uPA cleavage of a peptide substrate, NcarbobenzyloxyGlyGlyArg7amido4 methylcoumarin (ZGGRAMC). The IC50 value is < 80 nM. Test result meets the standard. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 43.73 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 48-60 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22 μm filtered solution in 50 mM HEPES, 300 mM NaCl, 1 mM TCEP (pH 7.5). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | PAI-1 (plasminogen activator inhibitor-1) is a member of plasminogen cascade with an inhibitory role in plasmin activation. PAI-1 is an important regulator of the fibrinolytic process and levels of this antifibrinolytic protein are elevated in diabetes and insulin resistant states. |
| Synonyms | PAI; PAI-1; Serpin E1; SERPINE1; PAI1; PLANH1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
